|
SEC61 Complex as a Novel Therapeutic Target to Enhance Immunotherapy Response in Glioblastoma
NU 2023-011
INVENTORS
Irina Balyasnikova*
Northwestern University Feinberg School of Medicine, Department of Neurological Surgery
Joseph Duffy
SHORT DESCRIPTION
A targeted therapeutic approach that inhibits the SEC61 complex to enhance responses to immunotherapy in glioblastoma.
BACKGROUND
Glioblastoma (GBM) is the most aggressive primary...
Published: 4/14/2026
|
Updated: 4/14/2026
|
Inventor(s):
Keywords(s): Brain cancer, Cancer/Oncology, Immunotherapy, Targeted therapy, Therapeutics
Category(s): Life Sciences > Therapeutics
|
|
Anti-TYRP1 Bi-specific T cell Engager for Treatment of TYRP1-expressing melanoma
NU 2022-123
INVENTORS
Irina Balyasnikova (Feinberg School of Medicine, Department of Neurological Surgery)*
Isabelle Le Poole (Feinberg School of Medicine, Department of Dermatology)*
SHORT DESCRIPTION
A bispecific T cell engager that targets CD3+ T cells and TYRP1-expressing melanoma cells.
BACKGROUND
Melanoma is the deadliest form of skin...
Published: 4/14/2026
|
Updated: 4/14/2026
|
Inventor(s):
Keywords(s): Biologic, Cancer/Oncology, Immunotherapy, Melanoma, Targeted therapy, Therapeutics
Category(s): Life Sciences > Therapeutics
|
|
Synthetic Receptors for IL-23
NU 2024-093
SHORT DESCRIPTION
Synthetic IL-23 receptors for cell engineering to enable real-time sensing and drive precise autoimmune and cancer immunotherapy interventions.
INVENTORS
Joshua Leonard*
McCormick School of Engineering, Department of Chemical and Biological Engineering
Aaron Morris
William...
Published: 4/14/2026
|
Updated: 4/14/2026
|
Inventor(s):
Keywords(s): Autoimmune disease, Cell engineering, Cell therapy, Diagnostics, IBD - Inflammatory bowel disease, Immunology, Immunotherapy, Inflammation, Targeted therapy, Therapeutics
Category(s): Life Sciences > Therapeutics, Life Sciences > Biomarkers & Biomedical Research Tools
|
|
Bi-specific Lipid Nanoparticles for Boosting Antitumor Immunity in Glioblastoma
NU 2022-151
SHORT DESCRIPTION
A bispecific lipid nanoparticle that bridges tumor-associated myeloid cells (TAMCs) and glioma cells by dual checkpoint blockade and simultaneously reprograms TAMCs into antitumor effectors via targeted delivery of a STING agonist.
INVENTORS
Maciej Lesniak*
Northwestern University Feinberg...
Published: 4/14/2026
|
Updated: 4/14/2026
|
Inventor(s):
Keywords(s): Brain cancer, Cancer/Oncology, Drug delivery, Immunotherapy, Nanoparticle, Nanotechnology, Targeted therapy, Therapeutics
Category(s): Life Sciences > Therapeutics
|
|
Neuronal nitric oxide synthase (nNOS) inhibitors for targeted therapy of melanoma and neurodegenerative disorders
NU 2025-113 (NU 2016-137, NU 2018-176, NU 2019-179, NU 2023-007, NU 2024-250, NU 2025-038)
INVENTORS
Richard Silverman (Weinberg College of Arts and Sciences, Department of Chemistry)
SHORT DESCRIPTION
Novel highly selective neuronal nitric oxide synthase (nNOS) inhibitors for targeted therapy of melanoma and other cancers with high expression...
Published: 4/14/2026
|
Updated: 4/1/2026
|
Inventor(s):
Keywords(s): ALS - Amyotrophic Lateral Sclerosis, AUTM26C1, BIAUTM1, Cancer/Oncology, Cardiology and Cardiovascular disease, Immunodeficiency, Immunology, Immunotherapy, Melanoma, Neurodegenerative disease, Neuroinflammation, nNOS, Small molecule, Targeted therapy, Therapeutics
Category(s): Life Sciences > Therapeutics
|
|
Covalent PRC2 Inhibitors for Advanced Cancer Therapeutics
SHORT DESCRIPTION
Covalent inhibitors and proteolysis-targeting chimera (PROTAC) degraders targeting components of the PRC2 complex (EZH and EED) to block both enzymatic and non-enzymatic functions, offering robust anti-tumor efficacy.
INVENTORS
Gary Schiltz (Weinberg College of Arts and Sciences, Department of Chemistry)*
Jindan...
Published: 4/14/2026
|
Updated: 3/5/2026
|
Inventor(s):
Keywords(s): AUTM26C1, BIAUTM1, Bladder cancer, Breast cancer, Cancer/Oncology, Covalent inhibitor, Lymphoma, Melanoma, PreSeed/Seed, Prostate cancer, PROTAC, Small molecule, Targeted protein degradation, Targeted therapy, Therapeutics
Category(s): Life Sciences > Therapeutics
|
|
Inhibition of BACH1 for pulmonary arterial hypertension therapy
LU 2024-222
INVENTORS
Youyang Zhao*
SHORT DESCRIPTION
This invention identifies a protein called BACH1 as a key driver of pulmonary arterial hypertension (PAH). By targeting and inhibiting BACH1, particularly in the pulmonary endothelium, this technology provides methods for preventing or reversing the abnormal thickening of pulmonary vasculature,...
Published: 3/5/2026
|
Updated: 3/5/2026
|
Inventor(s):
Keywords(s): Cardio-Pulmonary, Pulmonary disease, Targeted therapy, Therapeutics
Category(s): Life Sciences > Therapeutics
|
|
Antibodies for treatment of coronavirus disease
NU 2023-247
INVENTORS
Huiping Liu*
Deyu Fang*
Hannah Mubarak
Andrew Hoffmann
Nurmaa Dashzeveg
Lamiaa El-Shennawy
Juncheng Wei
Wuwei Tan
Yang Shen
SHORT DESCRIPTION
Computationally redesigned antibodies targeting SARS-CoV-2 for treating COVID-19.
BACKGROUND
The continuous evolution of SARS-CoV-2 has allowed the virus to escape most therapeutic...
Published: 2/26/2026
|
Updated: 2/26/2026
|
Inventor(s):
Keywords(s): Antibody, Artificial Intelligence & Machine Learning, Biologic, Infectious disease, Research tool, Targeted therapy, Therapeutics
Category(s): Life Sciences > Therapeutics
|
|
Netrin-1 mimetic peptide amphiphiles
Netrin-1 Mimetic Peptide Amphiphile Assemblies
NU 2024-174
INVENTORS
Samuel Stupp*
Cara Smith
Zaida Alvarez Pinto
SHORT DESCRIPTION
Nanofiber-shaped supramolecular assemblies that mimic netrin-1 bioactivity to stimulate neurite growth and synaptic maturation for enhanced CNS regeneration.
BACKGROUND
Neurotrophic factors are essential for...
Published: 2/20/2026
|
Updated: 2/20/2026
|
Inventor(s):
Keywords(s): AD - Alzheimer’s Disease, CNS - Central Nervous System, CVA - Cerebrovascular Accident, Nanomaterials, Nanotechnology, Neurodegenerative disease, Regenerative medicine, SCI - Spinal cord injury, Targeted therapy, Therapeutics
Category(s): Life Sciences > Therapeutics
|
|
Selective DOT1L Protein Degraders for Precision Cancer Therapy
NU 2022-081
INVENTORS
Sarki Abdulkadir (PI)*
Northwestern University Feinberg School of Medicine, Department of Urology
Gary Schiltz (PI)*
Weinberg College of Arts and Sciences, Department of Chemistry
SHORT DESCRIPTION
A small molecule PROTAC technology that degrades DOT1L protein for targeted treatment of leukemia and prostate...
Published: 4/7/2026
|
Updated: 2/3/2026
|
Inventor(s):
Keywords(s): AUTM26C1, BIAUTM1, Cancer/Oncology, Leukemia, Prostate cancer, PROTAC, Small molecule, Targeted protein degradation, Targeted therapy, Therapeutics
Category(s): Life Sciences > Therapeutics
|